FDJU:EURONEXT PARISFDJ United Analysis
Data as of 2026-03-15 - not real-time
€25.86
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
FDJ UNITED trades around €25.86, well below its DCF‑derived fair value of €57.9, implying a strong valuation gap. Technical signals are mixed: the price sits above the 20‑day and 50‑day SMAs (25.1 and 23.7) but below the 200‑day SMA (26.7), while the RSI of 62 points to modest overbought pressure and the MACD remains bullish. Volume is on a downtrend, raising a mild liquidity concern, yet the stock’s beta of 0.26 suggests limited market‑wide volatility, offset by a high 30‑day realized volatility of ~31%. The dividend yield is attractive at 8.1%, but a payout ratio exceeding 200% flags sustainability issues. Recent regulatory commentary highlights a “transformation in an environment marked by adverse factors” and a slight dip in turnover, underscoring sector‑specific headwinds.
Given the sizable valuation discount, modest revenue growth (≈10%), and the unsustainable dividend policy, the upside appears driven more by price correction than earnings acceleration. Investors should weigh the high regulatory risk and the company’s ongoing strategic shift against the attractive price relative to fundamentals, positioning FDJ UNITED as a potentially rewarding but cautiously approached investment.
Given the sizable valuation discount, modest revenue growth (≈10%), and the unsustainable dividend policy, the upside appears driven more by price correction than earnings acceleration. Investors should weigh the high regulatory risk and the company’s ongoing strategic shift against the attractive price relative to fundamentals, positioning FDJ UNITED as a potentially rewarding but cautiously approached investment.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near short‑term support and neutral trend direction
- Decreasing volume indicating modest liquidity pressure
- MACD bullish but limited upside in the near term
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap to DCF fair value
- Forward PE of 8.9 suggesting earnings expansion potential
- Technical bullish bias from MACD and SMA crossovers
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Structural undervaluation despite high dividend yield
- Potential upside from strategic transformation and market share gains
- Regulatory risk remains high, requiring ongoing monitoring
Key Metrics & Analysis
Financial Health
Revenue Growth10.60%
Profit Margin4.78%
P/E Ratio27.2
ROE16.25%
ROA5.70%
Debt/Equity232.45
P/B Ratio4.9
Op. Cash Flow€837.0M
Free Cash Flow€578.5M
Technical Analysis
TrendNeutral
RSI62.1
Support€22.46
Resistance€26.58
MA 20€25.10
MA 50€23.74
MA 200€26.71
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair Value€57.93
Target Price€29.00
Upside/Downside12.16%
GradeUndervalued
TypeBlend
Dividend Yield8.12%
Risk Assessment
Beta0.26
Volatility31.00%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.